Emergent BioSolutions (EBS) Tops Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
- Bel Fuse acquires dataMate ethernet business for $16 million
Emergent BioSolutions Reports Financial Results For First Quarter 2022
April 28, 2022 4:06 PM EDTReports Q1 2022 total revenues of $308M, in line with guidance, and Adjusted EBITDA of $36MTemporarily suspends CDMO guidance pending further clarity on COVID-19 vaccine requirements
GAITHERSBURG, Md., April 28, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2022.
Emergent remains focused on our strategic plan to grow within public health threat markets where we can positively impact patients and customers, said Robert G. Kramer, president and CEO of Emergent BioSolutions. Our diversified business model, disciplined operating... More
